Walk into any clinic in Mumbai, Delhi or Bengaluru today and the same question keeps coming up: if Ozempic and Wegovy are made of the same molecule, why does one cost more, why is only one officially approved for weight loss in India, and which one will actually work better for me?
Short answer: they are the same drug, semaglutide, but the dose and the legal indication are different.
That changes everything: who can prescribe it, how much weight you can realistically lose, what side effects to expect, and even what your insurance will cover.
Both are made by Novo Nordisk. Both are now available in India. But they are not interchangeable. Here is the full breakdown.
Key Takeaways At A Glance
| Same molecule, different doses. Both Ozempic and Wegovy contain semaglutide. Ozempic caps at 2 mg weekly, Wegovy goes up to 2.4 mg.Different India approvals. Wegovy is approved by CDSCO for weight management (June 2025). Ozempic is approved for type 2 diabetes only (Dec 2025). Weight loss with Ozempic is off-label.Wegovy wins on weight loss numbers. In the STEP 1 trial, Wegovy produced 14.9% average weight loss over 68 weeks vs roughly 6-7% with Ozempic in diabetes trials.Wegovy also reduces heart attack and stroke risk. The SELECT trial showed a 20% MACE reduction in adults with obesity and established heart disease. |
So, Is Ozempic The Same As Wegovy? (And Is Wegovy The Same As Semaglutide?)
Yes and no. Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist that mimics a gut hormone your body already makes.
This hormone tells your brain you are full, slows down how fast your stomach empties, and improves how your pancreas releases insulin.
Same molecule. Same manufacturer. Same once-weekly injection under the skin.
Where they split: the maximum dose and the official reason a doctor prescribes them.
- Ozempic maxes out at 2 mg per week and is officially approved in India for type 2 diabetes only.
- Wegovy goes up to 2.4 mg per week (plus a newer 7.2 mg high-dose version abroad) and is approved specifically for chronic weight management.
That single difference, the maintenance dose, is what drives every other difference between the two.
What’s The Approval Status In India Right Now?
This is where most online articles are out of date. Here is the current picture in 2026.
Wegovy In India
Wegovy landed in India in June 2025, launched by Novo Nordisk after approval from the Central Drugs Standard Control Organisation (CDSCO).
It is officially indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) who have at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea.
Wegovy is available in five doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. You start low and titrate up over about 16 weeks to reduce nausea and gut side effects.
Ozempic In India
Ozempic was approved by CDSCO in September 2025 and officially launched by Novo Nordisk on December 12, 2025. Its label in India is for type 2 diabetes management.
It is not approved for weight loss as a standalone indication, although it is widely used off-label because semaglutide causes weight loss as a side effect of how it works.
This off-label issue is now under regulatory scrutiny. In July 2025, the Delhi High Court directed CDSCO and DCGI to examine the off-label use of diabetes GLP-1 drugs like Ozempic for weight loss. The court flagged concerns about safety evaluations in Indian patients and the need for tighter regulation.
The Generics Wave That Changes Everything
On March 20, 2026, semaglutide’s patent expired in India. As reported by Reuters via Fierce Pharma, more than 40 Indian pharmaceutical companies are now launching generic semaglutide versions, including Sun Pharma (Noveltreat), Zydus (Semaglyn, Mashema, Altreme), Natco (with Eris Lifesciences), Mankind (Samakind), Dr Reddy’s, Cipla, Biocon and Lupin.
India became the first major market where semaglutide generics can compete freely, while patent protection continues in the US and Europe until the 2030s.
Practical takeaway: ask your doctor about both the branded and generic options. The generic landscape is moving fast and approvals are still rolling in.
Which Is Better For Weight Loss, Ozempic Or Wegovy? Here’s What The Trials Show
This is the question everyone wants answered, and there is solid clinical evidence to settle it. The data is consistent: higher dose, more weight loss.
Wegovy: The STEP 1 Trial Numbers
The pivotal trial for Wegovy was STEP 1 (Semaglutide Treatment Effect in People with Obesity 1), published in the New England Journal of Medicine in 2021.
- 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions, without diabetes.
- Randomised 2:1 to weekly semaglutide 2.4 mg or placebo, both with lifestyle counselling, for 68 weeks.
- Mean weight loss: −14.9% with Wegovy vs −2.4% with placebo. Treatment difference: −12.4 percentage points (p<0.001).
- 86.4% of Wegovy participants lost at least 5% of body weight, vs 31.5% on placebo.
- Absolute weight loss: −15.3 kg vs −2.6 kg with placebo.
Ozempic: How Much Weight Loss Does The Lower Dose Actually Deliver?
Ozempic was studied in the SUSTAIN trials, designed for blood sugar control in type 2 diabetes. Weight loss was a secondary outcome, not the primary goal. Across the SUSTAIN programme:
- In SUSTAIN 5, patients on Ozempic 1 mg lost on average 6.4 kg over 30 weeks. (Read the trial here.)
- In SUSTAIN 7, Ozempic 1 mg led to about 6.5 kg of weight loss over 40 weeks in patients with type 2 diabetes.
- In SUSTAIN FORTE, the higher 2 mg dose modestly outperformed 1 mg on weight and HbA1c.
The Head-To-Head Result You Want To See
The cleanest comparison comes from STEP 2, which directly tested both doses in the same trial population (adults with overweight or obesity AND type 2 diabetes):
- Wegovy 2.4 mg weekly: 9.64% mean weight loss at 68 weeks.
- Ozempic 1.0 mg weekly: 7.0% mean weight loss at 68 weeks.
- Placebo: 3.4% weight loss.
In plain terms: at the same trial, in the same patients, Wegovy delivered roughly 38% more weight loss than Ozempic. And remember, Wegovy participants in STEP 1 (non-diabetic) lost almost twice as much (14.9%) because non-diabetics generally respond more strongly to GLP-1 weight loss therapy than people with type 2 diabetes.
Ozempic Vs Wegovy: The Side-By-Side Comparison
Here is everything in one view.
| Feature | Ozempic | Wegovy |
| Active Ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| India Approval (CDSCO) | Type 2 diabetes only (Sep 2025) | Chronic weight management (June 2025) |
| India Launch Date | 12 December 2025 | June 2025 |
| Maximum Weekly Dose | 2 mg | 2.4 mg (7.2 mg HD approved abroad) |
| Available Doses | 0.25, 0.5, 1, 2 mg | 0.25, 0.5, 1, 1.7, 2.4 mg |
| Route & Frequency | Subcutaneous, once weekly | Subcutaneous, once weekly |
| Average Weight Loss | ~6-7% (in diabetes trials) | ~14.9% (in STEP 1) |
| Cardiovascular Benefit | CV risk reduction in T2D + heart disease | 20% MACE reduction in SELECT trial |
| Who It’s For | Adults with type 2 diabetes | Adults with BMI ≥30, or ≥27 with comorbidity |
| Insurance Coverage (India) | Typically not covered for weight loss | Typically not covered |
What Side Effects Should You Actually Expect?
Because Ozempic and Wegovy are the same drug, their safety profiles are essentially the same. The intensity of side effects is what differs, and it scales with the dose.
The Common Stuff (Mostly Gut-Related)
Across the STEP and SUSTAIN trials, the most common side effects were:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal pain
- Reduced appetite (this is part of how it works)
- Fatigue and headache, particularly during dose escalation
Most gut side effects are mild to moderate, transient, and improve as your body adjusts. They are also more pronounced during the dose-up phase, which is exactly why doctors titrate slowly over 16 weeks.
In SELECT, 10% of Wegovy patients discontinued treatment because of gut side effects, compared to 2% on placebo.
The Serious Stuff Your Doctor Will Screen For
- Pancreatitis: rare but serious; persistent severe abdominal pain needs urgent attention.
- Gallbladder disease: gallstones can occur, particularly with rapid weight loss.
- Medullary thyroid carcinoma risk: semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2.
- Kidney issues: dehydration from vomiting or diarrhoea can stress the kidneys.
- Diabetic retinopathy: rapid blood sugar drops can temporarily worsen retinopathy in some patients with diabetes.
In December 2025, CDSCO recommended approval for Novo Nordisk to update Wegovy’s package insert in India with revised safety and pharmacodynamic data, so the label you see in 2026 is more current than the original launch version.
What Indian Patients Should Particularly Watch For
Three specific points that don’t get enough attention in marketing material:
- Dehydration risk during summer months. GLP-1 vomiting plus 40°C heat is a faster path to acute kidney injury than the global trial population faced.
- Muscle mass loss. Roughly 25-40% of weight lost on GLP-1s can be lean mass. Protein intake of 1.2-1.6 g/kg body weight and resistance training are not optional. They are part of the treatment.
- Weight regain when you stop. The STEP 1 extension published in the journal Diabetes, Obesity and Metabolism showed that one year after stopping semaglutide, participants regained two-thirds of their lost weight. Obesity is chronic. Stopping the medicine without a maintenance plan undoes most of the progress.
Beyond Weight Loss: What Else Does Semaglutide Do?
This is where Wegovy has built a particularly strong case in the last two years.
The SELECT Trial Changed The Conversation
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial, published in the New England Journal of Medicine in 2023, enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but no diabetes.
- Wegovy 2.4 mg cut the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% vs placebo (HR 0.80; 95% CI 0.72-0.90; p<0.001).
- The benefit appeared within three months, well before any meaningful weight loss happened, suggesting a direct cardiovascular effect, not just a weight-mediated one.
- Risk reduction held across age, gender, ethnicity and starting BMI.
On the back of SELECT, Wegovy now has an FDA-approved indication for reducing cardiovascular risk in adults with established heart disease who are overweight or obese, even without diabetes.
Ozempic’s Track Record In Diabetes
Ozempic has its own strong cardiovascular evidence from the SUSTAIN 6 and FLOW trials in people with type 2 diabetes.
The FLOW trial showed a 24% reduction in the risk of kidney disease progression, kidney failure and cardiovascular death over three years in patients with T2D and chronic kidney disease.
So both drugs deliver beyond just the number on the scale. The difference is which population the benefit is proven in.
So Which One Is Right For You? A Practical Framework
This is the decision your doctor will help you make, but here is how it usually breaks down.
Wegovy Is Usually The Right Call If…
- Your primary goal is weight loss, not blood sugar control.
- Your BMI is 30 or higher, or 27+ with a weight-related condition like hypertension or sleep apnoea.
- You have established heart disease (the SELECT data is on your side).
- You want the highest possible weight loss outcome and your doctor agrees you can tolerate dose escalation.
Ozempic Is Usually The Right Call If…
- You have type 2 diabetes and need both glycaemic control AND modest weight loss.
- Your endocrinologist is targeting HbA1c reduction as the primary outcome.
- You have T2D plus chronic kidney disease (the FLOW trial supports this).
- You and your doctor have weighed the off-label conversation if weight is also a goal.
Who Should Avoid Both
- Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Anyone with a history of pancreatitis.
- Anyone who is pregnant, trying to conceive, or breastfeeding.
- People with severe gastroparesis or active gallbladder disease (relative contraindication).
- Adolescents (off-label in India outside of clinical supervision, although global STEP TEENS data exists for 12-17 year olds).
Common Questions People Are Asking
What’s the actual difference between Ozempic and Wegovy for weight loss in India?
The active drug, semaglutide, is the same. The difference is the maximum weekly dose (2 mg for Ozempic vs 2.4 mg for Wegovy) and the legal indication.
In India, only Wegovy is officially approved for weight loss. Ozempic is approved only for type 2 diabetes, and any weight loss use is off-label, which carries regulatory and ethical considerations your doctor must navigate.
Is Wegovy available in India and how does it compare to Ozempic?
Yes. Wegovy launched in India in June 2025, roughly six months before Ozempic. It is available in five dose strengths through standard pharmacy channels with a valid prescription.
Compared to Ozempic, Wegovy delivers more weight loss (the higher 2.4 mg dose and the dedicated obesity indication mean studies are designed around weight outcomes, not glycaemic ones).
Ozempic, on the other hand, has more years of cardiovascular and kidney data in the diabetes population specifically.
Which semaglutide product is better for weight loss: Ozempic or Wegovy?
For pure weight loss in adults without diabetes, Wegovy is the better-evidenced choice. The STEP 1 trial showed a 14.9% average weight loss over 68 weeks at the 2.4 mg dose. Ozempic at 1 mg typically produces around 6-7% weight loss in diabetes studies.
The dose, not the brand, is doing the work. That said, the right product depends on whether you have diabetes, what your BMI and comorbidities look like, and what your insurer and pharmacy can actually supply.
Is Ozempic the same as semaglutide?
Ozempic is a brand of semaglutide, not all of semaglutide. Semaglutide is the generic name for the molecule. Ozempic, Wegovy and Rybelsus (an oral tablet form) are all semaglutide brands made by Novo Nordisk for different indications and routes.
As of March 2026, there are also 40+ Indian generic versions of semaglutide hitting the market under brand names like Noveltreat, Semaglyn and Samakind.
Can a GP prescribe these, or do I need a specialist?
Legally, any qualified doctor can prescribe. Clinically, you want a doctor who is going to monitor your dose titration, screen for contraindications, track muscle mass and protein intake, and plan a maintenance strategy.
Endocrinologists, bariatric physicians, and trained obesity medicine doctors are the safer bet, especially for the 16-week dose-up window when most side effects show up.
Will I regain the weight if I stop?
In all likelihood, yes. The STEP 1 extension trial found that one year after stopping semaglutide, participants regained roughly two-thirds of the weight they had lost.
Obesity is a chronic biological condition. Like blood pressure medicine, the drug works while you take it. A maintenance dose, lifestyle scaffolding, and ongoing medical supervision are the actual long-term plan, not a sprint.
The Bottom Line
Ozempic and Wegovy are the same molecule, semaglutide, at different doses and approved for different reasons in India.
If you have type 2 diabetes: your doctor will likely consider Ozempic. Weight loss is a welcome bonus, not the primary target.
If your primary goal is weight loss and you meet the BMI criteria: Wegovy is the on-label, better-evidenced option.
Either way, semaglutide is a chronic-disease medicine, not a 12-week quick fix. Treat it like long-term blood pressure or cholesterol therapy. Pair it with protein, resistance training, and a doctor who is going to monitor you through every dose change.
This article is for informational purposes only and is not a substitute for medical advice. Always consult a qualified physician before starting any GLP-1 medication.
